The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Clinical Trials, Intermediate Risk Prostate Cancer

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT06111781
Phase: PHASE2
Trial Summary: The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients.

Stereotactic body radiotherapy (SBRT) alone or Stereo – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Yale University
Acronym:

Pin It on Pinterest